Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDKAIC)

Drug Name

ISIS-SGLT2 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting SLC5A2 messenger RNA (SLC5A2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bexagliflozin	DMK56G0	Type 2 diabetes	5A11	Approved	[2]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[3]
KURARINONE	DMH0G8W	Discovery agent	N.A.	Investigative	[3]
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[4]
Alstiphyllanine F	DMKRAEW	Discovery agent	N.A.	Investigative	[4]
Kushenol N	DMY13UR	Discovery agent	N.A.	Investigative	[3]
Alstiphyllanine E	DMTNQ5E	Discovery agent	N.A.	Investigative	[4]
Burnamine-17-O-3',4',5'-trimethoxybenzoate	DMBO0WI	Discovery agent	N.A.	Investigative	[4]
Alstiphyllanine D	DM2FLDJ	Discovery agent	N.A.	Investigative	[4]
O-spiroketal glucoside	DM3FS62	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
4	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
5	ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.